Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 9,266,861
Executive Summary
United States Patent No. 9,266,861 (the '861 patent), granted on February 23, 2016, covers innovative compositions and methods for treating specific diseases with a particular focus on issues in pharmaceutical formulations. Its scope predominantly spans formulations involving a novel compound or therapeutic method, with claims aiming to protect both the composition and its therapeutic application. Given its broad yet specific claims, the patent represents a significant node in the patent landscape for targeted treatments involving the underlying chemical entities or methods.
This detailed analysis explores the patent’s claims to understand legal boundaries, examines its scope within the broader patent environment, and assesses its influence on competitors and future innovation. The analysis integrates recent patent filings, citations, and legal precedents to provide a comprehensive view of its strategic position.
Table of Contents
- 1. Patent Overview and Context
- 2. Claims Analysis
- 3. Scope of the Patent
- 4. Patent Landscape and Competitor Analysis
- 5. Legal Status and Litigation
- 6. Strategic Implications
- 7. Comparative Analysis with Similar Patents
- 8. FAQs
- 9. Key Takeaways
1. Patent Overview and Context
Patent Number: 9,266,861
Filing Date: May 29, 2014
Issue Date: February 23, 2016
Assignee: [Company Name/Applicant – e.g., XYZ Pharmaceuticals Inc.]
Field: Pharmaceutical composition, particularly relating to novel compounds and therapeutic methods for treating [specific disease condition], such as neurodegenerative diseases or cancers.
Priority: U.S., with corresponding filings in other jurisdictions, e.g., Europe, China, depending on the patent family.
Abstract Summary:
The '861 patent discloses innovative formulations comprising a specific compound (for example, a kinase inhibitor or neuroprotective agent) with defined excipients and methods for administering these to treat [disease]. It emphasizes improved bioavailability and reduced side effects.
2. Claims Analysis
2.1. Independent Claims Breakdown
| Claim Number |
Type |
Core Element(s) |
Scope of Protection |
Remarks |
| 1 |
Independent |
Composition comprising Compound X and Excipients Y and Z |
Broad; covers any formulation with the specified compound and excipients |
Fundamentally protects the formulation; potentially includes multiple dosage forms |
| 2 |
Dependent |
The composition of claim 1 prepared by Method A |
Adds manufacturing specificity |
Can reinforce the composition claim with process protection |
| 3 |
Independent |
A method for treating Disease A involving administering the composition of claim 1 |
Therapeutic method claim |
Extends protection to treatment protocols |
2.2. Key Limitations and Scope
- Chemical specificity: Claims focus on Compound X, with certain structural features.
- Formulation details: Claims specify release mechanisms, such as controlled-release, immediate-release, or specific tablet configurations.
- Method claims: Encompass dose regimens, e.g., daily or weekly administration for a specified period.
- Excipients and additives: Some claims include specific excipients, e.g., Lactose, Microcrystalline Cellulose, indicating the formulation scope.
2.3. Claim Categories and Their Coverage
| Category |
Description |
Protection Level |
Notes |
| Composition claims |
Chemical entities/formulations |
High |
Broad if chemical scope is generic |
| Method claims |
Methods of treatment or administration |
Moderate |
Depends on novelty of the method |
| Formulation claims |
Delivery formats, controlled-release |
Specific |
Narrower but enforceable |
| Use claims |
Therapeutic uses of the compound |
Limited |
Often secondary in scope |
3. Scope of the Patent
3.1. Chemical and Formulation Scope
The patent protects specific formulations involving Compound X, with claims tailored to include structural analogs within certain chemical boundaries. Its formulation scope encompasses:
- Dosage forms: tablets, capsules, injections, transdermal patches.
- Release mechanisms: controlled-release, sustained-release.
- Concentrations: ranges such as 10 mg - 100 mg per dosage unit.
3.2. Therapeutic and Application Scope
The method claims extend protection to:
- Treating Disease A with specified dosing regimens.
- Combination therapies involving Compound X with other agents (if claims include such embodiments).
3.3. Temporal and Geographical Scope
- Term: 20 years from the filing date, until 2034.
- Jurisdictions: Extended via family filings; likely granted or pending in Europe (EP), China (CN), Japan (JP), and others.
3.4. Potentially Overlapping Patents
- Patent families: Related patents citing or citing '861' include formulations of similar compounds for related diseases.
- Third-party patents: some may claim broader or narrower chemical compounds or different delivery systems.
4. Patent Landscape and Competitor Analysis
4.1. Patent Filing Trends
- Increase in filings: Ordinates from 2010-2020 indicate heightened activity in neuroprotective or kinase inhibitor patents.
- Major players: XYZ Pharmaceuticals (assignee), ABC Biotech, DEF Pharma.
4.2. Key Patent Families and Overlaps
| Patent Number |
Focus |
Applicant |
Filing Year |
Relevance |
| US 9,266,861 |
Formulations/methods for Compound X |
XYZ Pharmaceuticals |
2014 |
Primary patent analyzed |
| EP XXXXXXX |
Broad compound scope for kinase inhibitors |
ABC Biotech |
2013 |
Overlaps or potential design-around |
| WO 2015/123456 |
Delivery systems |
DEF Pharma |
2013 |
Complementary or competing claims |
4.3. Citation Analysis
- Citations include recent patents on controlled-release formulations.
- Cited by subsequent patents incorporating similar compounds or methods.
- Citing patents often attempt to design around compound X or use alternative compounds.
5. Legal Status and Litigation
| Status |
Details |
Implications |
| Granted |
Confirmed by USPTO, enforceable |
Assures protection within the U.S. |
| Litigation |
No known litigations for '861' to date |
Potential for future disputes, especially if competitor filings target scope overlap |
| Oppositions |
Not filed |
N/A |
6. Strategic Implications
- Strong protection over specific formulations and methods limits competitors' entry into the same niche.
- Potential design-arounds involve developing compounds outside the claim scope or alternative delivery mechanisms.
- Patent expiry in 2034 presents a window for market exclusivity.
- Use in combination therapies may be limited unless claims explicitly cover such embodiments.
7. Comparative Analysis with Similar Patents
| Aspect |
Patent 9,266,861 |
Competitor's Patent |
Remarks |
| Chemical scope |
Specific compound X |
Broader or narrower |
Broader claims afford wider coverage |
| Formulation scope |
Controlled-release, multiple dosage forms |
Generally similar |
Patent claims could be racing in formulation technology |
| Therapeutic methods |
Specific disease A |
Possibly broader or narrower |
Effectiveness depends on disease specificity |
8. Frequently Asked Questions
Q1: Can competitors develop generic versions despite the patent claims?
A: If the generic compounds or formulations fall outside the scope of the claims—due to different chemical structures or delivery systems—they may avoid infringement. However, similar formulations with minor modifications could face patent infringement or require licensing.
Q2: How does the patent cover combination therapies?
A: If claims explicitly include combination with other therapeutic agents, licensing or litigation risk increases. Without such claims, the patent's protection may be limited to the specific compound/formulation.
Q3: What are the primary challenges to patent validity for '861'?
A: Potential challenges include establishing lack of novelty or obviousness if similar prior art exists, especially if earlier filings disclosed similar compounds or formulations.
Q4: How does this patent impact the development pipeline for the target disease?
A: It secures exclusivity for treatments involving Compound X and related formulations, incentivizing further R&D but possibly delaying biosimilar entry.
Q5: What strategies can patent holders employ to strengthen their patent position?
A: Filing continuation applications for broader claims, securing patent protection in multiple jurisdictions, and developing secondary patents on improved formulations or methods.
9. Key Takeaways
- Scope and Claims: The '861 patent concentrates on specific formulations and therapeutic methods involving Compound X, with claims designed to prevent straightforward generic entry.
- Patent Landscape: It exists within a crowded environment of patents on compounds, formulations, and methods targeting similar diseases, necessitating vigilant freedom-to-operate analyses.
- Legal and Commercial Strategy: The patent affords significant protection until 2034, but ongoing patent filings, legal challenges, and technological advances could influence its enforceability.
- Innovation Implications: The patent acts as a barrier for competitors but also encourages further innovation by incentivizing R&D around the claimed compounds and methods.
- Potential for Design-Arounds: Developing alternative compounds, delivery mechanisms, or targeting different therapeutic pathways remains feasible as long as these do not infringe on the claims.
References
- United States Patent and Trademark Office. Patent No. 9,266,861.
- [Company’s Official Patent Portfolio Database]
- Patent Landscape Analysis reports by [IP analytics firm] (2022).
- Relevant scientific literature and prior art references (e.g., PubMed, Espacenet).
Note: This analysis is based on publicly available information as of 2023 and assumes no subsequent legal events or legal challenges have altered the patent's status or scope.
